Science Links Japan | Serine Proteinase Inhibitor 9 Can Be Recognized by Cytotoxic T Lymphocytes of Epithelial Cancer Patients.

Serine Proteinase Inhibitor 9 Can Be Recognized by Cytotoxic T Lymphocytes of Epithelial Cancer Patients.

Accession number;02A0236724

Title;Serine Proteinase Inhibitor 9 Can Be Recognized by Cytotoxic T Lymphocytes of Epithelial Cancer Patients.

Author; TANAKA K (Kurume Univ. School Of Medicine, Fukuoka) HARASHIMA N (Kurume Univ. School Of Medicine, Fukuoka) NIIYA F (Kurume Univ. School Of Medicine, Fukuoka) MIYAGI Y (Kurume Univ. School Of Medicine, Fukuoka) HIDA N (Kurume Univ. School Of Medicine, Fukuoka) OCHI M (Kurume Univ. School Of Medicine, Fukuoka) IMAI N (Kurume Univ. School Of Medicine, Fukuoka) ITOH K (Kurume Univ. School Of Medicine, Fukuoka) SHICHIJO S (Kurume Univ. School Of Medicine, Fukuoka)

Journal Title;Jpn J Cancer Res

Journal Code:F0633A

ISSN:0910-5050

VOL.93;NO.2;PAGE.198-208(2002)

Figure&Table&Reference;FIG.7, TBL.4, REF.37

Pub. Country;Japan

Language;English

Abstract;Serine proteinase inhibitor 9 (PI-9) inhibits granzyme B-mediated apoptosis and interleukin-1.BETA.-converting enzyme activity. In this study, we report that the PI-9 gene encodes antigenic epitopes recognized by the HLA-A24-restricted and tumor-reactive cytotoxic T lymphocytes (CTLs) of epithelial cancer patients. Screening of an autologous cDNA library using a CTL line recognizing HLA-A24+ tumor cells resulted in the isolation of a cDNA, which had an identical coding region to the previously described PI-9 genes. PI-9 gene was expressed in approximately three-fourths of epithelial cancer cell lines and all leukemic cell lines tested. It was also expressed in normal peripheral blood mononuclear cells (PBMCs), but not in a normal fibroblast cell line. CTL sublines contained T cells capable of recognizing the PI-9292-300 and PI-9348-356 peptides among 13 different peptides having the HLA-A24 binding motifs. These two peptides were recognized by the CTL line in a dose-dependent and HLA class-I-restricted manner, and also possessed the ability to induce HLA class I-restricted and tumor-reactive CTLs in PBMCs from HLA-A24+ cancer patients. These results demonstrate that PI-9 is recognized by HLA class I-restricted and tumor-reactive CTLs of epithelial cancer patients. (author abst.)

Related Articles;